DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for blue color blindness — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleBlue color blindness maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for blue color blindness is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
opsin 1, short wave sensitive (OPN1SW) — OPN1SW is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet retdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8Y02 · 2.61 Å · ligand RETINAL (RET). Experimental structure, not a prediction.
What the evidence adds up to
Blue-blocking lenses, tested in five healthy participants aged 23 to 39, impaired colour contrast sensitivity only for blue colours, and most clearly at low contrasts. Lenses with lower transmittance profiles caused greater reductions. The study used Crizal Prevencia, Blue Guardian, and Blu-OLP lenses against a clear control, measuring thresholds with a visual search task. The authors concluded that while blue-blocking lenses may reduce blue hazard light, they unintentionally reduce colour contrast sensitivity at low light levels.
A 2024 review of colour blindness describes it as a retinal disease with forms including achromatopsia, red-green, and blue-yellow colour blindness. The review covers genetic understanding and treatment approaches such as gene therapy, pharmacological interventions, and visual aids. It mentions promising results from clinical trials but also ongoing challenges for achieving effective and long-lasting outcomes. No specific drug, trial result, or survival data is reported in this review.
A 1953 book review notes the tenth edition of the Ishihara Tests for Colour-Blindness, published in Tokyo and London, containing 27 pages and 38 plates. No experimental results or treatment data are provided.
No drug has been tested in a clinical trial for blue colour blindness specifically. The 2024 review mentions pharmacological interventions in general but gives no concrete numbers, response rates, or survival data. What is missing is any completed or ongoing trial that tests a repurposed drug in patients with blue colour blindness, along with the funding and patient stratification needed to design such a study.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Clinical and Experimental Optometry · 2020 · 20 citations
Effect of blue-blocking lenses on colour contrast sensitivity
AbstractCLINICAL RELEVANCE: There is a significant unintended consequences of blue-blocking lenses on visual behaviour, particularly for the detection of colour. Optometrists need to be mindful of this when prescribing the appropriate blue-blocking lenses for individuals who work in environments in which blue light is prevalent. BACKGROUND: The selective reduction in visible wavelengths transmitted through commercially available blue-blocking lenses is known to influence object appearance and luminance contrast, and also potentially object colour contrast. The present study investigated the effect of a number of commercially available blue-blocking lenses on colour contrast sensitivity in normal individuals under low and high contrast stimulus conditions. METHODS: Five healthy participants (one man and four women), aged between 23 and 39-years, were recruited for this study. Crizal Prevencia (Essilor), Blue Guardian (Opticare), and Blu-OLP (GenOp) lenses were examined in this study in comparison to a control lens (clear lens without blue-filtering coating). In Experiment 1, colour contrast thresholds were measured using a visual search colour detection task in which the colour (CIE Lu'v' red, green, blue and yellow) of the target circle stimulus (randomly located in an annulus of achromatic circles) was systematically reduced using a staircase procedure. As blue-blocking lenses selectively block blue light, in Experiment 2, colour contrast thresholds were specifically quantified for a range of short wavelengths near the attenuation transmittance range of the blue-blocking lenses tested. RESULTS: Experiments 1 and 2 showed that colour contrast was impaired only for blue colours, and this was most evident at low contrasts. Additionally, the blue-blocking lenses with lower transmittance profiles led to greater reductions in colour contrast sensitivity and shown to affect colour contrast thresholds. CONCLUSION: Our results suggest that while reducing blue light potentially minimises the harmful effect of blue hazard light, blue-blocking lenses can unintentionally reduce colour contrast sensitivity, particularly at low light levels.
Frontiers in Neuroscience · 2024 · 13 citations · open access
Dyschromatopsia: a comprehensive analysis of mechanisms and cutting-edge treatments for color vision deficiency
AbstractColor blindness is a retinal disease that mainly manifests as a color vision disorder, characterized by achromatopsia, red-green color blindness, and blue-yellow color blindness. With the development of technology and progress in theory, extensive research has been conducted on the genetic basis of color blindness, and various approaches have been explored for its treatment. This article aims to provide a comprehensive review of recent advances in understanding the pathological mechanism, clinical symptoms, and treatment options for color blindness. Additionally, we discuss the various treatment approaches that have been developed to address color blindness, including gene therapy, pharmacological interventions, and visual aids. Furthermore, we highlight the promising results from clinical trials of these treatments, as well as the ongoing challenges that must be addressed to achieve effective and long-lasting therapeutic outcomes. Overall, this review provides valuable insights into the current state of research on color blindness, with the intention of informing further investigation and development of effective treatments for this disease.
AbstractJournal Article Book Reviews Get access Tests for Colour-Blindness Shinobu Ishibara , 10th ed. Tokyo : Nippon Isho Shuppan Co. Ltd. ; London : H. K. Lewis & Co. Ltd. , 1951 . 27 pages; 38 plates. 21 × 15 cm. £3 15s. R. W. Pickford R. W. Pickford Search for other works by this author on: Oxford Academic PubMed Google Scholar British Medical Bulletin, Volume 9, Issue 1, 1953, Page 82, https://doi.org/10.1093/oxfordjournals.bmb.a074316 Published: 01 January 1953
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
